The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation

Simple item page
dc.contributor.authorOuellet, Véronique
dc.contributor.authorAprikian, Armen
dc.contributor.authorBergeron, Alain
dc.contributor.authorBrimo, Fadi
dc.contributor.authorBristow, Robert G
dc.contributor.authorChevalier, Simone
dc.contributor.authorDrachenberg, Darrel
dc.contributor.authorFazli, Ladan
dc.contributor.authorFleshner, Neil E
dc.contributor.authorGleave, Martin
dc.contributor.authorKarakiewicz, Pierre
dc.contributor.authorKlotz, Laurence
dc.contributor.authorLacombe, Louis
dc.contributor.authorLattouf, Jean-Baptiste
dc.contributor.authorvan der Kwast, Theodorus
dc.contributor.authorSquire, Jeremy A
dc.contributor.authorLatour, Mathieu
dc.contributor.authorTrudel, Dominique
dc.contributor.authorMes-Masson, Anne-Marie
dc.contributor.authorSaad, Fred
dc.date.accessioned2018-10-01T03:22:28Z
dc.date.issued2018-09-10
dc.date.updated2018-10-01T03:22:28Z
dc.description.abstractAbstract Background Refinement of parameters defining prostate cancer (PC) prognosis are urgently needed to identify patients with indolent versus aggressive disease. The Canadian Prostate Cancer Biomaker Network (CPCBN) consists of researchers from four Canadian provinces to create a validation cohort to address issues dealing with PC diagnosis and management. Methods A total of 1512 radical prostatectomy (RP) specimens from five different biorepositories affiliated with teaching hospitals were selected to constitute the cohort. Tumoral and adjacent benign tissues were arrayed on tissue microarrays (TMAs). A patient clinical database was developed and includes data on diagnosis, treatment and clinical outcome. Results Mean age at diagnosis of patients in the cohort was 61 years. Of these patients, 31% had a low grade (≤6) Gleason score (GS), 55% had GS 7 (40% of 3 + 4 and 15% of 4 + 3) and 14% had high GS (≥8) PC. The median follow-up of the cohort was 113 months. A total of 34% had a biochemical relapse, 4% developed bone metastasis and 3% of patients died from PC while 9% died of other causes. Pathological review of the TMAs confirmed the presence of tumor and benign tissue cores for > 94% of patients. Immunohistochemistry and FISH analyses, performed on a small set of specimens, showed high quality results and no biorepository-specific bias. Conclusions The CPCBN RP cohort is representative of real world PC disease observed in the Canadian population. The frequency of biochemical relapse and bone metastasis as events allows for a precise assessment of the prognostic value of biomarkers. This resource is available, in a step-wise manner, for researchers who intend to validate prognostic biomarkers in PC. Combining multiple biomarkers with clinical and pathologic parameters that are predictive of outcome will aid in clinical decision-making for patients treated for PC.
dc.identifier.citationBMC Urology. 2018 Sep 10;18(1):78
dc.identifier.urihttps://doi.org/10.1186/s12894-018-0392-x
dc.identifier.urihttp://hdl.handle.net/1993/33477
dc.language.rfc3066en
dc.rightsopen accessen_US
dc.rights.holderThe Author(s).
dc.titleThe Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
12894_2018_Article_392.pdf
Size:
2.21 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.24 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship
Rady Faculty of Health Sciences Scholarly Works